Haemonetics Co. (NYSE:HAE) Shares Purchased by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH boosted its position in Haemonetics Co. (NYSE:HAE) by 88.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 517,086 shares of the medical instruments supplier’s stock after acquiring an additional 242,956 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Haemonetics were worth $32,861,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of HAE. Thrivent Financial for Lutherans boosted its stake in shares of Haemonetics by 14.9% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier’s stock valued at $98,716,000 after acquiring an additional 164,111 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Haemonetics by 1.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 992,229 shares of the medical instruments supplier’s stock worth $77,470,000 after purchasing an additional 10,990 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Haemonetics by 0.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 801,049 shares of the medical instruments supplier’s stock worth $62,802,000 after purchasing an additional 5,668 shares during the last quarter. Fisher Asset Management LLC increased its stake in shares of Haemonetics by 3.2% in the fourth quarter. Fisher Asset Management LLC now owns 711,774 shares of the medical instruments supplier’s stock valued at $55,575,000 after purchasing an additional 22,265 shares during the period. Finally, Northern Trust Corp raised its position in shares of Haemonetics by 16.1% during the 4th quarter. Northern Trust Corp now owns 678,261 shares of the medical instruments supplier’s stock worth $52,959,000 after buying an additional 93,848 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on HAE. Needham & Company LLC dropped their target price on Haemonetics from $104.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. Raymond James reiterated a “strong-buy” rating and issued a $105.00 price objective (down from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Wall Street Zen lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Tuesday, May 13th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $100.00 price objective on shares of Haemonetics in a research report on Tuesday, May 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $97.89.

Haemonetics Trading Down 0.8%

Shares of Haemonetics stock opened at $71.53 on Thursday. Haemonetics Co. has a 12-month low of $55.30 and a 12-month high of $94.99. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The firm has a market capitalization of $3.44 billion, a price-to-earnings ratio of 28.16, a PEG ratio of 1.11 and a beta of 0.36. The firm’s 50 day simple moving average is $64.63 and its two-hundred day simple moving average is $69.42.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.02. The firm had revenue of $330.60 million during the quarter, compared to analysts’ expectations of $329.38 million. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. Haemonetics’s revenue was down 3.5% compared to the same quarter last year. During the same period last year, the business earned $0.90 earnings per share. Analysts predict that Haemonetics Co. will post 4.55 EPS for the current year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.